Daiwa Securities Group Inc. - CRINETICS PHARMACEUTICALS IN ownership

CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 63 filers reported holding CRINETICS PHARMACEUTICALS IN in Q2 2019. The put-call ratio across all filers is - and the average weighting 0.2%.

Quarter-by-quarter ownership
Daiwa Securities Group Inc. ownership history of CRINETICS PHARMACEUTICALS IN
ValueSharesWeighting
Q2 2024$12
-7.7%
2730.0%0.00%
Q1 2024$13
+30.0%
2730.0%0.00%
Q4 2023$10
+66.7%
273
+37.2%
0.00%
Q3 2023$6
+50.0%
1990.0%0.00%
Q2 2023$4
+33.3%
1990.0%0.00%
Q1 2023$3
-25.0%
1990.0%0.00%
Q4 2022$4
-99.9%
1990.0%0.00%
Q3 2022$4,0000.0%1990.0%0.00%
Q2 2022$4,000
+33.3%
199
+50.8%
0.00%
Q1 2022$3,000
-25.0%
1320.0%0.00%
Q4 2021$4,000
+33.3%
1320.0%0.00%
Q3 2021$3,000
+200.0%
132
+112.9%
0.00%
Q2 2021$1,0000.0%620.0%0.00%
Q1 2021$1,0000.0%620.0%0.00%
Q4 2020$1,000
-50.0%
62
-59.5%
0.00%
Q3 2019$2,000
-50.0%
1530.0%0.00%
Q2 2019$4,000
+33.3%
1530.0%0.00%
Q1 2019$3,000
-57.1%
153
-30.5%
0.00%
Q4 2018$7,0002200.00%
Other shareholders
CRINETICS PHARMACEUTICALS IN shareholders Q2 2019
NameSharesValueWeighting ↓
Saturn V Capital Management LP 479,681$21,484,9128.12%
New Leaf Venture Partners, L.L.C. 141,000$6,315,3907.68%
STEMPOINT CAPITAL LP 551,095$24,683,5457.25%
EcoR1 Capital, LLC 4,155,375$186,119,2465.69%
ACUTA CAPITAL PARTNERS, LLC 135,141$6,052,9655.10%
First Light Asset Management, LLC 1,200,508$53,770,7534.71%
Ikarian Capital, LLC 588,818$26,373,1584.59%
Paradigm Biocapital Advisors LP 2,513,302$112,570,7974.31%
MPM BioImpact LLC 557,184$24,956,2713.88%
Cormorant Asset Management, LP 1,350,000$60,466,5003.49%
View complete list of CRINETICS PHARMACEUTICALS IN shareholders